| Literature DB >> 31350456 |
Xiaohui Ji1, Junguo Zhang1, Li Liu1, Ziqiang Lin2, Lucheng Pi1, Zhifeng Lin1, Nana Tian1, Xinqi Lin1, Sidong Chen1, Xinfa Yu3, Yanhui Gao4.
Abstract
As a long non-coding RNA (lncRNA) and a transcriptional regulator, Metastasis associated lung adenocarcioma transcript-1 (MALAT-1) has been reported to be associated with proliferation and metastasis of hepatocellular carcinoma (HCC). However, the effects of MALAT-1 single nucleotide polymorphisms (SNPs) on HCC remains poorly understood. This study, including 624 HCC cases and 618 controls, aimed to explore the potential associations between three common tagSNPs at MALAT-1 and HCC risk in a Southern Chinese population. No significant associations were observed between the three tagSNPs and HCC risk under any genetic models after adjusting for potential confounders. Additionally, there were no any significant associations in the stratified analysis, combined effect analysis, and multifactor dimensionality reduction (MDR) analysis. Unification analysis of mediation and interaction on HCC risk further showed that four decomposition of total effects ((controlled direct effect (CDE), the reference interaction effect (INTref), the mediated interaction effect (INTmed), or the pure indirect effect (PIE)) were also not significant. Neither was the association between the MALAT-1 SNPs and progression factors of HCC, including TNM staging, metastasis, and cancer embolus; Overall, this study suggested that tagSNPs rs11227209, rs619586, and rs3200401 at MALAT-1 were not significantly associated with HCC susceptibility. Nevertheless, large population-based studies are warranted to further explore the role of MALAT-1 SNPs in HCC incidence and development.Entities:
Mesh:
Substances:
Year: 2019 PMID: 31350456 PMCID: PMC6659651 DOI: 10.1038/s41598-019-47165-w
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Associations between MALAT-1 SNPs and HCC risk in the case-control study.
| Genotypes | Cases N = 624 (%) | Controls N = 618 (%) | Crude OR (95% CI) |
| Adjusted OR (95% CI)a |
|
|---|---|---|---|---|---|---|
| rs11227209 | ||||||
| CC | 551 (88.44) | 558 (90.44) | 1.00 | 1.00 | ||
| CG | 68 (10.92) | 57 (9.24) | 1.21 (0.83–1.75) | 0.318 | 1.26 (0.80–1.99) | 0.322 |
| GG | 4 (0.64) | 2 (0.32) | 2.03 (0.37–11.10) | 0.416 | 2.16 (0.30–15.39) | 0.442 |
| Dominant | — | — | 1.24 (0.86–1.78) | 0.254 | 1.29 (0.83–2.03) | 0.260 |
| Recessive | — | — | 1.99 (0.36–10.89) | 0.429 | 2.11 (0.30–15.00) | 0.457 |
| Additive | — | — | 1.24 (0.88–1.75) | 0.216 | 1.28 (0.84–1.93) | 0.251 |
| C | 1170 (93.90) | 1173 (95.06) | 1.00 | 1.00 | ||
| G | 76 (6.10) | 61 (4.94) | 1.25 (0.88–1.77) | 0.208 | 1.31 (0.86–2.00) | 0.217 |
| rs619586 | ||||||
| AA | 522 (83.92) | 531 (85.92) | 1.00 | 1.00 | ||
| AG | 93 (14.95) | 82 (13.27) | 1.15 (0.84–1.59) | 0.382 | 1.10 (0.74–1.64) | 0.627 |
| GG | 7 (1.13) | 5 (0.81) | 1.42 (0.45–4.52) | 0.548 | 2.61 (0.68–10.04) | 0.164 |
| Dominant | — | — | 1.17 (0.86–1.60) | 0.326 | 1.17 (0.80–1.72) | 0.422 |
| Recessive | — | — | 1.40 (0.44–4.42) | 0.571 | 2.57 (0.67–9.89) | 0.170 |
| Additive | — | — | 1.16 (0.87–1.55) | 0.301 | 1.21 (0.85–1.71) | 0.288 |
| A | 1137 (91.40) | 1144 (92.56) | 1.00 | 1.00 | ||
| G | 107 (8.60) | 92 (7.44) | 1.17 (0.88–1.56) | 0.290 | 1.22 (0.86–1.75) | 0.270 |
| rs3200401 | ||||||
| CC | 464 (74.60) | 453 (73.42) | 1.00 | 1.00 | ||
| CT | 149 (23.95) | 152 (24.64) | 0.96 (0.74–1.24) | 0.741 | 0.97 (0.70–1.35) | 0.868 |
| TT | 9 (1.45) | 12 (1.94) | 0.73 (0.31–1.76) | 0.485 | 0.71 (0.24–2.10) | 0.537 |
| Dominant | — | — | 0.94 (0.73–1.21) | 0.636 | 0.95 (0.69–1.31) | 0.765 |
| Recessive | — | — | 0.74 (0.31–1.77) | 0.499 | 0.72 (0.24–2.11) | 0.544 |
| Additive | — | — | 0.93 (0.74–1.17) | 0.542 | 0.95 (0.71–1.26) | 0.713 |
| C | 1077 (86.58) | 1058 (85.74) | 1.00 | 1.00 | ||
| T | 167 (13.42) | 176 (14.26) | 0.93 (0.74–1.17) | 0.546 | 0.94 (0.71–1.25) | 0.668 |
Abbreviations: HCC, hepatocellular carcinoma; OR, odds ratio; CI, confidence interval; SNPs, single nucleotide polymorphisms.
aAdjusted by age, gender, drinking and smoking status, HBsAg status, history of ditch water drinking, and family history of cancers.
Combined Effect of the three SNPs in MALAT-1 on HCC risk.
| Number of risk allelesa | Cases N = 624 (%) | Controls N = 618 (%) | Crude OR (95% CI) |
| Adjusted ORb (95% CI) |
|
|---|---|---|---|---|---|---|
| 0–2 | 522 (84.33) | 537 (87.18) | 1.00 | 1.00 | ||
| 3–4 | 91 (14.70) | 75 (12.18) | 1.25 (0.90–1.73) | 0.186 | 1.28 (0.85–1.90) | 0.249 |
| 5–6 | 6 (0.97) | 4 (0.65) | 1.54 (0.43–5.50) | 0.504 | 2.27 (0.50–10.01) | 0.285 |
Abbreviations: OR, odds ratio; CI, confidence interval; SNPs, single nucleotide polymorphisms.
aThe risk alleles were the G, G, and C for rs11227209, rs619586 and rs3200401 respectively.
bAdjusted by age, gender, drinking and smoking status, HBsAg status, history of ditch water drinking, and family history of cancers.
Proportions of the effect of SNPs on HCC risk due to mediation and/or interaction with HBV status.
| Genotype | Component | Excess Relative Risk (95% CI) |
| Proportion Attributable (%) |
|---|---|---|---|---|
| rs11227209 | CDE | −0.030 (−0.117, 0.057) | 0.504 | 11.60 |
| INTref | −0.219 (−0.760, 0.322) | 0.428 | 85.70 | |
| INTmed | 0.002 (−0.046, 0.051) | 0.924 | −0.92 | |
| PIE | −0.009 (−0.199, 0.180) | 0.924 | 3.61 | |
|
| −0.217 (−0.755, 0.322) | 0.430 | 84.78 | |
|
| −0.007 (−0.148, 0.135) | 0.924 | 2.69 | |
|
| −0.249 (−0.763, 0.265) | 0.343 | 97.31 | |
|
| −0.256 (−0.78, 0.269) | 0.339 | 100.00 | |
| rs619586 | CDE | −0.004 (−0.641, 0.633) | 0.991 | −125.71 |
| INTref | 0.009 (−1.541, 1.559) | 0.991 | 297.53 | |
| INTmed | 0.000 (−0.033, 0.032) | 0.991 | −6.19 | |
| PIE | −0.002 (−0.331, 0.327) | 0.990 | −65.63 | |
|
| 0.009 (−1.509, 1.526) | 0.991 | 291.34 | |
|
| −0.002 (−0.364, 0.359) | 0.991 | −71.82 | |
|
| 0.005 (−0.908, 0.918) | 0.991 | 171.82 | |
|
| 0.003 (−0.548, 0.555) | 0.991 | 100.00 | |
| rs3200401 | CDE | −0.02 (−0.084, 0.044) | 0.539 | −6.31 |
| INTref | 0.307 (−0.264, 0.877) | 0.292 | 96.71 | |
| INTmed | 0.008 (−0.037, 0.054) | 0.723 | 2.61 | |
| PIE | 0.022 (−0.093, 0.137) | 0.705 | 6.99 | |
|
| 0.315 (−0.273, 0.903) | 0.294 | 99.32 | |
|
| 0.030 (−0.128, 0.189) | 0.706 | 9.60 | |
|
| 0.287 (−0.277, 0.850) | 0.319 | 90.40 | |
|
| 0.317(−0.285, 0.919) | 0.302 | 100.00 |
Abbreviations: CDE: Controlled Direct Effect; INTref: Reference Interaction Effect; INTmed: Mediated Interaction Effect; PIE: Pure Indirect Effect;
Overall Interaction Effect: INTref + INTmed;
Overall Mediated Effect = Indirect Effect: INTmed + PIE; Direct Effect: CDE + INTref;
Total Effect: CDE + INTref + INTmed + PIE = CDE + Overall Interaction + PIE = CDE + INTref + Overall Mediated = Direct + Indirect.
Adjusted by age, gender, drinking and smoking status, HBsAg status, history of ditch water drinking, and family history of cancers.
Associations between the MALAT-1 SNPs and clinicopathologic characteristics in patients with HCC (N = 624).
| Genotypes | TNM stage | Metastasis | Cancer embolus | ||||||
|---|---|---|---|---|---|---|---|---|---|
| I + II | III + IV | Adjusted ORa (95% CI) | No | Yes | Adjusted ORa (95% CI) | No | Yes | Adjusted ORa (95% CI) | |
| rs11227209 | |||||||||
| CC | 94 (88.68) | 413 (87.69) | 1.00 | 429 (87.73) | 93 (90.29) | 1.00 | 461 (88.15) | 57 (91.94) | 1.00 |
| CG + GG | 12 (11.32) | 58 (12.31) | 1.07 (0.55–2.08) | 60 (12.27) | 10 (9.71) | 0.72 (0.35–1.48) | 62 (11.86) | 5 (8.07) | 0.60 (0.23–1.58) |
| rs619586 | |||||||||
| AA | 88 (83.02) | 393 (83.62) | 1.00 | 405 (82.99) | 89 (86.41) | 1.00 | 436 (83.53) | 55 (88.71) | 1.00 |
| AG + GG | 18 (16.98) | 77 (16.38) | 0.97 (0.55–1.71) | 83 (17.01) | 14 (13.59) | 0.75 (0.41–1.39) | 86 (16.48) | 7 (11.29) | 0.65 (0.28–1.49) |
| rs3200401 | |||||||||
| CC | 75 (72.12) | 350 (74.15) | 1.00 | 364 (74.59) | 76 (73.79) | 1.00 | 391 (74.90) | 42 (67.74) | 1.00 |
| CT + TT | 29 (27.89) | 122 (25.85) | 0.96 (0.59–1.56) | 124 (25.41) | 27 (26.21) | 1.08 (0.66–1.77) | 131 (25.10) | 20 (32.26) | 1.55 (0.87–2.78) |
Abbreviations: OR, odds ratio; CI, 95% confidence interval; SNPs, single nucleotide polymorphisms.
aAdjusted by age, gender, drinking and smoking status, HBsAg status, history of ditch water drinking, and family history of cancers.